We then performed an independent validation of this RF predictor using data from the US Oncology 02–103 breast cancer trial (GSE42822 [10]), in which 25 patients with stage II-III HER2-positive breast cancer received trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.